Reckamp K - Search Results

1

Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells.

Herrmann A, Kortylewski M, Kujawski M, Zhang C, Reckamp K, Armstrong B, Wang L, Kowolik C, Deng J, Figlin R, Yu H. Herrmann A, et al. Among authors: reckamp k. Cancer Res. 2010 Oct 1;70(19):7455-64. doi: 10.1158/0008-5472.CAN-10-0736. Epub 2010 Sep 14. Cancer Res. 2010. PMID: 20841481 Free PMC article.

2

Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer.

Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B, Baratelli F, Huang M, Batra RK, Dubinett SM. Sharma S, et al. Among authors: reckamp k. Cancer Res. 2005 Jun 15;65(12):5211-20. doi: 10.1158/0008-5472.CAN-05-0141. Cancer Res. 2005. PMID: 15958566

3

The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma.

Mestas J, Burdick MD, Reckamp K, Pantuck A, Figlin RA, Strieter RM. Mestas J, et al. Among authors: reckamp k. J Immunol. 2005 Oct 15;175(8):5351-7. doi: 10.4049/jimmunol.175.8.5351. J Immunol. 2005. PMID: 16210641

4

Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma.

Yang SC, Batra RK, Hillinger S, Reckamp KL, Strieter RM, Dubinett SM, Sharma S. Yang SC, et al. Among authors: reckamp kl. Cancer Res. 2006 Mar 15;66(6):3205-13. doi: 10.1158/0008-5472.CAN-05-3619. Cancer Res. 2006. PMID: 16540672

5

A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.

Reckamp KL, Krysan K, Morrow JD, Milne GL, Newman RA, Tucker C, Elashoff RM, Dubinett SM, Figlin RA. Reckamp KL, et al. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3381-8. doi: 10.1158/1078-0432.CCR-06-0112. Clin Cancer Res. 2006. PMID: 16740761 Clinical Trial.

6

Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin.

Reckamp KL, Gardner BK, Figlin RA, Elashoff D, Krysan K, Dohadwala M, Mao J, Sharma S, Inge L, Rajasekaran A, Dubinett SM. Reckamp KL, et al. J Thorac Oncol. 2008 Feb;3(2):117-24. doi: 10.1097/JTO.0b013e3181622bef. J Thorac Oncol. 2008. PMID: 18303430 Free article. Clinical Trial.

7

Chemokines as therapeutic targets in renal cell carcinoma.

Reckamp KL, Strieter RM, Figlin RA. Reckamp KL, et al. Expert Rev Anticancer Ther. 2008 Jun;8(6):887-93. doi: 10.1586/14737140.8.6.887. Expert Rev Anticancer Ther. 2008. PMID: 18533798 Free PMC article. Review.

8

The role of targeting mammalian target of rapamycin in lung cancer.

Pal SK, Figlin RA, Reckamp KL. Pal SK, et al. Clin Lung Cancer. 2008 Nov;9(6):340-5. doi: 10.3816/CLC.2008.n.049. Clin Lung Cancer. 2008. PMID: 19073516 Review.

9

CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer.

Reckamp KL, Figlin RA, Burdick MD, Dubinett SM, Elashoff RM, Strieter RM. Reckamp KL, et al. BMC Cancer. 2009 Jun 29;9:213. doi: 10.1186/1471-2407-9-213. BMC Cancer. 2009. PMID: 19563666 Free PMC article.

10

STAT3: a target to enhance antitumor immune response.

Lee H, Pal SK, Reckamp K, Figlin RA, Yu H. Lee H, et al. Among authors: reckamp k. Curr Top Microbiol Immunol. 2011;344:41-59. doi: 10.1007/82_2010_51. Curr Top Microbiol Immunol. 2011. PMID: 20517723 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

189 results

Search Page

Filters